baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

MEDIWOUND LTD IS-,01/ IL0011316309 /

2024-04-18 10:54:38 AM	Chg. -1.9000	Volume	Bid9:37:01 PM	Ask9:58:52 PM	High	Low
16.1000EUR	-10.56%	105 Turnover: 1,733	-Bid Size: -	-Ask Size: -	16.6000	16.1000

GlobeNewswire 03-14 MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 02-12 MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ...

GlobeNewswire 02-05 MediWound to Participate in Two Upcoming Investor Conferences

GlobeNewswire 01-09 MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include P...

GlobeNewswire 2023-12-28 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for...

GlobeNewswire 2023-12-21 MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its E...

GlobeNewswire 2023-11-21 MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire 2023-11-21 MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commerci...

GlobeNewswire 2023-11-14 MediWound to Report Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-13 MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Pati...

GlobeNewswire 2023-11-08 MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in ...

GlobeNewswire 2023-10-11 MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

GlobeNewswire 2023-10-09 MediWound Deploys NexoBrid® for Emergency Supply

GlobeNewswire 2023-09-26 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for...

GlobeNewswire 2023-09-21 MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Bu...

GlobeNewswire 2023-09-11 MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Ass...

GlobeNewswire 2023-09-05 MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conferenc...

GlobeNewswire 2023-08-15 MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

GlobeNewswire 2023-08-15 MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

GlobeNewswire 2023-08-15 MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

GlobeNewswire 2022-03-29 MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 20...

GlobeNewswire 2022-03-22 MediWound Announces Exercise of Over-Allotment Option

GlobeNewswire 2022-03-21 MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic W...

GlobeNewswire 2022-03-17 MediWound Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire 2022-03-10 MediWound Announces Closing of Public Offering of Ordinary Shares

MEDIWOUND LTD IS-,01/ IL0011316309 /

If you wish to receive reply to your feedback, please provide your email address.